Assessment Of Interferonβ-1b On Quality Of Life In Patients With Multiple Sclerosis

Background and Objectives :Multiple sclerosis(MS) is a common immune-mediated central nervous system disease that its main pathological features is white matter demyelination and axonal damage,which commonly occurs in young and middle-aged persons, especially can be seen in women. MS can highly disable patients, not only damages their physical and mental, but also influences the patient’s quality of life, increasing their economic burden. Clinical commonly used drugs such as hormones, interferon and so on. Interferon βis recommended as the first-line therapy for RRMS by 《Multiple Sclerosis diagnosis and treatment of Chinese expert consensus(Version 2011)》for it can reduce frequency of MS disease, alleviate nerve damage and decrease the incidence of disability as well as its reliable curative effect. Because most patients are young adults, whether the quality of life improved is of very important significance for the patient, through the treatment of interferon-β, but the effect of interferon beta on the quality of life of patients with MS is unclear. Abroad has do some research and follow-up work on the aspect of by using interferonβ, if the quality of life of patients with multiple sclerosis can be improved, but there is no clear result. While domestic research on this aspect is very scarce. Mostly domestic patients use interferonβ-1b to treatment, so the study on interferonβ-1b that if it can improve the quality of life of MS patients is particularly important. This study through the change of depression, anxiety,nervous system function, cognition and the quality of life in using interferon before and after, to evaluate the effect of interferon in patients with multiple sclerosis.Material and Methods:We summarized the 23 cases of MS in China-Japan Union Hospital of Jilin University from January 2012 to January 2016, who use IFNβ-lb in remission. After admission, there were two experenced doctors using the MSQOL-54, EDSS score, HAMA, HAMD scale to find out the correlation between age, disease duration, EDSS, anxiety, depression and quality of life. According the score of MSQOL-54, EDSS, HAMA, HAMD, Mo CA scale to assess the effect of MS patients treated with IFNβ-1b at baswline and at months 6 and 12. Use SPSS 18.0 software for statistical analysis of data, and analyze by using t test, repetitive measure analysis of variance, and Pearson correlation. If P<0.05,there has statistically significant.Results:In this study we summarized 23 patients, 7 cases of men, 16 cases of women, male: female = 1:2.29. mean age 34.91±8.38 years. The disease course from one to four yeas, The average duration 1.98±0.87 years. Among them Relapsing-Remitting multiple sclerosis has 20 cases(86.96%), Secondary-Progressive multiple sclerosis in 3 cases(13.04%), Primary-Progressive multiple sclerosis in 0 cases, Progressive-Relapsing multiple sclerosis in 0 cases.1. Between MS patients and normal, the quality of life and cognitive function scores were lower, anxiety and depression were more serious than normal(P <0.01).2. Most aspects of quality of life in patients with multiple sclerosis are negatively correlated with age, EDSS, HAMA and HAMD, but positively correlated with Mo CA.(1)Among them pain is negatively correlated with age(P=0.024).(2)Physical function, pain, social function and overall quality of life are negatively correlated with EDSS(P=0.023; P=0.001; P=0.029; P=0.013).(3) Physical function, pain, emotional well-being, energy, health distress, social function, cognitive function and overall quality of life are negatively correlated with HAMA(P=0.001; P=0.025; P=0.004; P=0.019; P=0.001; P=0.002; P=0.002).(4)Physical function, pain, emotional well-being, energy, health distress, social function, cognitive function and overall quality of life are negatively correlated with HAMD(P=0.001; P=0.018; P=0.001; P=0.010; P=0.045; P=0.001; P=0.010; P=0.001).(5) Role limitation due to emotional problems, pain, energy, health perceptions, social function are positively correlated with Mo CA score(P=0.016; P=0.012; P=0.005; P=0.008; P=0.001).(6)The disease course made less difference on the QOL score(P > 0.05).3. IFNβ-lb therapy has no impact on anxiety, depression, cognitive impairment and disability of MS patients in the one year(P>0.05).Our findings suggest that IFNβ-lb therapy maybe has no impact on the most aspects of QOL of MS patients in the one year, but emotional well-being(P=0.04) and role limitations due to emotional problems(P=0.03) are statistically significant. It means that after treatment with IFNβ-lb, MS patients in terms of emotional well-being and role limitations due to emotional problems has to improved.Conclusion:1. MS patients have a low quality of life and cognitive function, accompanied with anxiety and depression.2. The main factors influencing the quality of lives in patients with MS are EDSS score, anxiety, depression, cognitive, and age.3. IFNβ-lb therapy maybe has a little impact on the QOL of MS patients within a year, reflected in terms of emotional well-being and role limitations due to emotional in the list of MSQOL- 54 have to improved.